A Study of Necitumumab in the First-Line Treatment of Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC)

NCT01763788 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

192

Enrollment

INDUSTRY

Sponsor class

Conditions

Squamous Non-small Cell Lung Cancer

Interventions

DRUG: Necitumumab
DRUG: Gemcitabine
DRUG: Cisplatin

Sponsor

Eli Lilly and Company